

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Emcor 5 mg film-coated tablets
Emcor 10 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Emcor 5 mg: Each tablet contains 5 mg Bisoprolol fumarate (equivalent to 4.2mg bisoprolol).

Emcor 10 mg: Each tablet contains 10 mg Bisoprolol fumarate (equivalent to 8.4mg bisoprolol).

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Emcor 5 mg:
Film-coated tablet
Yellowish-white, heart shaped, scored and film-coated tablet.

Emcor 10 mg:
Film-coated tablet
Pale orange-light orange, heart shaped, scored and film-coated tablet.

The tablet can be divided into equal halves.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

In the management of hypertension and the management of angina pectoris.

4.2 Posology and method of administration

Route of administration: Oral

Posology

Adults:

The usual dose is 10mg once daily, with a maximum recommended dose of 20mg per day. In some patients 5mg per day may be adequate.

Patients with renal or hepatic impairment:

In patients with final stage impairment of renal function (creatinine clearance <20ml/minute) or liver function, the dose should not exceed 10mg bisoprolol once daily. Experience with the use of bisoprolol in renal dialysis patients is limited; however there is no evidence that the dosage regimen needs to be altered.

Older people:

No dosage adjustment is normally required, but 5mg per day may be adequate. In some patients, as for other adults, dosage may have to be reduced in cases of severe renal or hepatic dysfunction.

Paediatric population:

There is no paediatric experience with bisoprolol, therefore, its use cannot be recommended for children.

In patients with ischaemic heart disease, treatment should not be withdrawn abruptly; gradual dosage reduction over 1-2 weeks is recommended.

4.3 Contraindications

Bisoprolol is contra-indicated in patients with:

- acute heart failure or during episodes of heart failure decompensation requiring i.v. inotropic therapy
- cardiogenic shock
- second or third degree AV block (without a pacemaker)
- sick sinus syndrome
- sinoatrial block
- bradycardia (heart rate less than 60 beats/min prior to start of therapy)
- hypotension (systolic blood pressure < 100mmHg)
- severe bronchial asthma
- severe forms of peripheral arterial occlusive disease and Raynaud's syndrome
- untreated phaeochromocytoma (see section 4.4)
- metabolic acidosis
- hypersensitivity to the active substance or to any of the excipients listed in section 6.1

4.4 Special warnings and special precautions for use

Bisoprolol must be used with caution in:

- heart failure (the treatment of stable chronic heart failure with bisoprolol has to be initiated with a special titration phase [for details, see SPC for bisoprolol indicated for the treatment of stable chronic heart failure])
- bronchial asthma, obstructive airways disease

Although cardioselective (beta1) beta-blockers may have less effect on lung function than non-selective beta-blockers, as with all beta-blockers, these should be avoided in patients with obstructive airways diseases, unless there are compelling clinical reasons for their use. Where such reasons exist, Emcor may be used with caution. In patients with obstructive airways diseases, the treatment with bisoprolol should be started at the lowest possible dose and patients should be carefully monitored for new symptoms (e.g., dyspnea, exercise intolerance, cough). In bronchial asthma or other chronic obstructive lung diseases, which may cause symptoms, bronchodilating therapy may have to be given concomitantly. Occasionally an increase of the airway resistance may occur in patients with asthma; therefore the dose of β_2 -stimulants may have to be increased.

- diabetes mellitus with large fluctuations in blood glucose values; symptoms of hypoglycaemia can be masked
- strict fasting
- ongoing desensitisation therapy.
- AV block of first degree
- Prinzmetal's angina: Cases of coronary vasospasm have been observed. Despite its high beta1-selectivity, angina attacks cannot be completely excluded when bisoprolol is administered to patients with Prinzmetal's angina.
- peripheral arterial occlusive disease (intensification of complaints may occur particularly during the start of therapy)
- general anaesthesia.
In patients undergoing general anaesthesia beta-blockade reduces the incidence of arrhythmias and myocardial ischemia during induction and intubation, and the post-operative period. It is currently recommended that maintenance of beta-blockade be continued peri-operatively. The anaesthetist must be aware of beta-blockade because of the potential for interactions with other drugs, resulting in bradyarrhythmias, attenuation of the reflex tachycardia and the decreased reflex ability to compensate for blood loss. If it is thought necessary to withdraw beta-blocker therapy before surgery, this should be done gradually and completed about 48 hours before anaesthesia.

As with other β -blockers, bisoprolol may increase both the sensitivity towards allergens and the severity of anaphylactic reactions. Adrenaline treatment does not always give the expected therapeutic effect.

Patients with psoriasis or with a history of psoriasis should only be given β -blockers (e.g. bisoprolol) after carefully balancing the benefits against the risks.

In patients with pheochromocytoma bisoprolol must not be administered until after alpha-receptor blockade.

Under treatment with bisoprolol the symptoms of a thyrotoxicosis may be masked.

The cessation of therapy with bisoprolol should not be done abruptly unless clearly indicated. For further information, see section 4.2.

4.5 Interaction with other medicinal products and other forms of interaction

Combinations not recommended:

Calcium antagonists such as verapamil and to a lesser extent diltiazem:
Negative influence on contractility and atrio-ventricular conduction.
Intravenous administration of verapamil in patients on beta-blocker treatment may lead to profound hypotension and atrioventricular block.

Centrally-acting antihypertensive drugs (e.g. clonidine methyldopa, moxonidine, rilmenidine): Concomitant use of centrally-acting antihypertensive drugs may lead to reduction of heart rate and cardiac output and to vasodilatation. Abrupt withdrawal may increase the risk of 'rebound hypertension'.

Combinations to be used with caution

Calcium antagonists of the dihydropyridine type such as nifedipine:
Concomitant use may increase the risk of hypotension, and an increase in the risk of a further deterioration of the ventricular pump function in patients with heart failure cannot be excluded.

Class-I antiarrhythmic drugs (e.g. disopyramide, quinidine):
Effect on atrio-ventricular conduction time may be potentiated and negative inotropic effect may be increased.

Class-III antiarrhythmic drugs (e.g. amiodarone): Effect on atrio-ventricular conduction time may be potentiated.

Parasympathomimetic drugs: Concomitant use may increase atrio-ventricular conduction time and the risk of bradycardia.

Topical beta-blockers (e.g. eye drops for glaucoma treatment) may add to the systemic effects of bisoprolol.

Insulin and oral antidiabetic drugs: Intensification of blood sugar lowering effect. Blockade of β -adrenoceptors may mask symptoms of hypoglycaemia.

Concomitant use with antihypertensive agents as well as with other medicines with blood pressure lowering potential (e.g. tricyclic antidepressants, barbiturates, phenothiazines) may increase the risk of hypotension.

Anaesthetic agents: Attenuation of the reflex tachycardia and increase of the risk of hypotension. (For further information on general anaesthesia see also section 4.4).

Digitalis glycosides: Reduction of heart rate, increase of atrio-ventricular conduction time.

Non-steroidal anti-inflammatory drugs (NSAIDs): NSAIDs may reduce the hypotensive effect of bisoprolol.

β -sympathomimetics (e.g. isoprenaline, dobutamine): combination with bisoprolol may reduce the effect of both agents.

Sympathomimetics that activate β - and α - adrenoceptors: Combination with bisoprolol may unmask the alpha-adrenoceptor-mediated vasoconstrictor effects of these agents leading to blood pressure increase and exacerbated intermittent claudication. . Such interactions are considered to be more likely with non-selective β - blockers.

Sympathomimetic agents: Combination with bisoprolol may reduce the effect of both agents. Higher doses of epinephrine may be necessary for treatment of allergic reactions.

Combinations to be considered:

Mefloquine: increased risk of bradycardia.

Monoamineoxidase inhibitors (except MAO-B inhibitors): Enhanced hypotensive effect of β -blockers but also risk of hypertensive crisis.

4.6 Fertility, pregnancy and lactation

Pregnancy

Bisoprolol has pharmacological effects that may cause harmful effects on pregnancy and/or the foetus/newborn. In general, β - blockers reduce placental perfusion, which has been associated with growth retardation, intrauterine death, abortion or early labour. Adverse effects (e.g. hypoglycaemia and bradycardia) may occur in the foetus and newborn infant. If treatment with β -adrenoceptor blockers is necessary, β_1 -selective adrenoceptor blockers are preferable.

Bisoprolol should not be used during pregnancy unless clearly necessary. If treatment with bisoprolol is considered necessary, the uteroplacental blood flow and the fetal growth should be monitored. In case of harmful effects on pregnancy or the fetus alternative treatment should be considered. The newborn infant must be closely monitored. Symptoms of hypoglycaemia and bradycardia are generally to be expected within the first 3 days.

Breastfeeding

It is not known whether this drug is excreted in human milk. Therefore, breastfeeding is not recommended during administration of bisoprolol.

4.7 Effects on ability to drive and use machines

In a study with coronary heart disease patients bisoprolol did not impair driving performance. However, due to individual variations in reactions to the drug, the ability to drive a vehicle or to operate machinery may be impaired. This should be considered particularly at start of treatment and upon change of medication as well as in conjunction with alcohol.

4.8 Undesirable effects

The following definitions apply to the frequency terminology used hereafter:

Very common ($\geq 1/10$)

Common ($\geq 1/100$, to $< 1/10$)

Uncommon ($\geq 1/1,000$, to $< 1/100$)

Rare ($\geq 1/10,000$, to $< 1/1,000$)

Very rare ($< 1/10,000$)

Frequency not known (cannot be estimated from available data)

Cardiac disorders:

Uncommon: AV-conduction disturbances, worsening of pre-existing heart failure, bradycardia.

Investigations:

Rare: increased triglycerides, increased liver enzymes (ALAT, ASAT).

Nervous system disorders:

Common: dizziness*, headache*.

Rare: Syncope

Eye disorders:

Rare: reduced tear flow (to be considered if the patient uses lenses).

Very rare: conjunctivitis.

Ear and labyrinth disorders:

Rare: hearing disorders.

Respiratory, thoracic and mediastinal disorders:

Uncommon: bronchospasm in patients with bronchial asthma or a history of obstructive airways disease.

Rare: allergic rhinitis.

Gastrointestinal disorders:

Common: gastrointestinal complaints such as nausea, vomiting, diarrhoea, constipation.

Skin and subcutaneous tissue disorders:

Rare: hypersensitivity reactions (pruritus, flush, rash and angioedema).

Very rare: beta-blockers may provoke or worsen psoriasis or induce psoriasis-like rash, alopecia.

Musculoskeletal and connective tissue disorders:

Uncommon: muscular weakness and cramps.

Vascular disorders:

Common: feeling of coldness or numbness in the extremities, hypotension.

Uncommon: Orthostatic hypotension.

General disorders:

Common: fatigue*

Uncommon: asthenia.

Hepatobiliary disorders:

Rare: hepatitis.

Reproductive system and breast disorders:

Rare: erectile dysfunction.

Psychiatric disorders:

Uncommon: sleep disorder, depression.

Rare: nightmares, hallucinations.

*These symptoms especially occur at the beginning of the therapy. They are generally mild and often disappear within 1-2 weeks.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:

HPRA Pharmacovigilance

Website: www.hpra.ie

4.9 Overdose

Symptoms:

The most common signs expected with overdosage of a β -blocker are bradycardia, hypotension, bronchospasm, acute cardiac insufficiency and hypoglycaemia. To date few cases of overdose (maximum: 2000 mg) with bisoprolol have been reported. Bradycardia and/or hypotension were noted. All patients recovered. There is a wide interindividual variation in sensitivity to one single high dose of bisoprolol; patients with heart failure are probably particularly sensitive.

Management:

In general, if overdose occurs, bisoprolol treatment should be stopped and supportive and symptomatic treatment should be provided. Limited data suggest that bisoprolol is hardly dialysable. Based on the expected pharmacological actions and recommendations for other β -blockers, the following general measures should be considered when clinically warranted:

Bradycardia: Administer intravenous atropine. If the response is inadequate, isoprenaline or another agent with positive chronotropic properties may be given cautiously. Under some circumstances, transvenous pacemaker insertion may be necessary.

Hypotension: Intravenous fluids and vasopressors should be administered. Intravenous glucagon may be useful.

AV block (second or third degree): Patients should be carefully monitored and treated with isoprenaline infusion or transvenous cardiac pacemaker insertion.

Acute worsening of heart failure: Administer i.v. diuretics, inotropic agents, vasodilating agents.

Bronchospasm: Administer bronchodilator therapy such as isoprenaline, β_2 -sympathomimetic drugs and/or aminophylline.

Hypoglycaemia: Administer i.v. glucose.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: β - blocking agents, selective (C07AB07)

Mechanism of action:

Bisoprolol is a potent, highly β_1 -selective adrenoreceptor blocking agent devoid of intrinsic sympathomimetic activity and without relevant membrane stabilising activity.

As with other β_1 -blocking agents, the mode of action in hypertension is not clear but it is known that bisoprolol markedly depresses plasma renin activity.

In patients with angina, the blockade of β_1 -receptors reduces heart action and thus reduces oxygen demand. Hence bisoprolol is effective in eliminating or reducing the symptoms.

5.2 Pharmacokinetic properties

Bisoprolol is absorbed almost completely from the gastrointestinal tract. Together with the very small first pass effect in the liver, this results in a high

bioavailability of approximately 90%. The drug is cleared equally by the liver and kidney.

The plasma elimination half-life (10-12 hours) provides 24 hours efficacy following a once daily dosage. About 95% of the drug substance is excreted through the kidney, half of this is as unchanged bisoprolol. There are no active metabolites in man.

5.3 Preclinical safety data

Not applicable

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

excipients

Silica Colloidal anhydrous

Magnesium stearate

Crospovidone

Microcrystalline cellulose

Maize starch

Calcium hydrogen phosphate anhydrous

coating

Iron oxide Red E172 (10mg only)

Iron oxide Yellow E172

Dimeticone

Macrogol 400

Titanium Dioxide E171

Hypromellose

6.2 Incompatibilities

Not applicable

6.3 Shelf life

5 years

6.4 Special precautions for storage

Do not store above 30°C.

6.5 Nature and contents of container

Cartons containing aluminium/PVC blister packs of 4, 14 or 28 tablets. Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

No special requirements

7. MARKETING AUTHORISATION HOLDER

Merck Serono (Ireland) Limited
4045 Kingswood Road
Citywest Business Campus
Dublin 24
Ireland

8. MARKETING AUTHORISATION NUMBERS

PA 2286/2/1
PA 2286/2/2

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of First Authorisation: 30th June, 1988
Date of latest renewal 30th June, 2003

10. DATE OF REVISION OF THE TEXT

06 November 2020